Huixia Li, Bin Wang, Qin Li, Qing Li, Jie Qiao, Dongping Lin, Chunhua Sui, Lin Ye, Hualing Zhai, Boren Jiang, Ningjian Wang, Bing Han, Mengda Jiang, Xiaofeng Tao, Ziyang Shao, Chenfang Zhu, Yubo Ma, Ping Xiong, Jing Sun, Huifang Zhou, Yingli Lu
BACKGROUND: Intravenous glucocorticoid (IVGC) remains the main treatment for moderate-to-severe and active thyroid-associated ophthalmopathy (TAO). However, a substantial number (20-30%) of active moderate-to-severe TAO patients may not respond to IVGC. Some patients may have disease progression despite IVGC treatment or relapse after steroid withdrawal. OBJECTIVES: To analyze risk factors for clinical activity and predictive factors for clinical outcomes of 4.5 g IVGC therapy in patients with moderate-to-severe TAO...
June 22, 2023: Endocrine Research